DURAND REMY 4

Accession 0001626199-24-000074

CIK 0001626199other

View on SEC.gov Company Profile

Filed

May 9, 8:00 PM ET

Accepted

May 10, 7:25 PM ET

Size

22.4 KB

Accession

0001626199-24-000074

Insider Transaction Report

Form 4

Period: 2024-05-08

ALPINE IMMUNE SCIENCES, INC.ALPN

DURAND REMY

Chief Business Officer

Transactions

Exercise/Conversion
Common Stock
2024-05-08$6.51/sh+25,000$162,750→ 72,949 total
Exercise/Conversion
Common Stock
2024-05-08$4.09/sh+12,365$50,573→ 85,314 total
Exercise/Conversion
Common Stock
2024-05-08$3.23/sh+38,078$122,992→ 123,392 total
Exercise/Conversion
Common Stock
2024-05-08$13.20/sh+9,845$129,954→ 47,949 total
Exercise/Conversion
Common Stock
2024-05-08$4.76/sh+10,000$47,600→ 133,392 total
Exercise/Conversion
Stock Option (Right to buy)
2024-05-08−9,845→ 70,155 total
Exercise: $13.20Exp: 2031-01-04→ Common Stock (9,845 underlying)
Exercise/Conversion
Stock Option (Right to buy)
2024-05-08−25,000→ 0 total
Exercise: $6.51Exp: 2029-02-05→ Common Stock (25,000 underlying)
Exercise/Conversion
Stock Option (Right to buy)
2024-05-08−12,365→ 2,635 total
Exercise: $4.09Exp: 2029-06-12→ Common Stock (12,365 underlying)
Exercise/Conversion
Stock Option (Right to buy)
2024-05-08−38,078→ 26,922 total
Exercise: $3.23Exp: 2030-01-22→ Common Stock (38,078 underlying)
Exercise/Conversion
Stock Option (Right to buy)
2024-05-08−10,000→ 0 total
Exercise: $4.76Exp: 2028-11-05→ Common Stock (10,000 underlying)

Footnotes (7)

[F1]Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024.
[F2]The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
[F3]One-fourth (1/4) of the shares subject to the option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
[F4]One-fourth (1/4) of the shares subject to the option will vest on February 6, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
[F5]One-fourth (1/4) of the shares subject to the option will vest on May 1, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
[F6]One-fourth (1/4) of the shares subject to the option will vest on January 23, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
[F7]One-fourth (1/4) of the shares subject to the option will vest on October 8, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.

Documents

1 file

4
wk-form4_1715383504.xmlPrimary
FORM 4

Issuer

ALPINE IMMUNE SCIENCES, INC.

CIK 0001626199

→

Entity typeother

Related Parties

filerCIK 0001973027

Filing Metadata

Form type: 4
Filed: May 9, 8:00 PM ET
Accepted: May 10, 7:25 PM ET
Size: 22.4 KB

View on SEC.gov